- Home
- TEI vs CCCC Comparison
TEI vs CCCC Comparison
Compare TEI & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEI
- CCCC
- Stock Information
- Founded
- TEI 1993
- CCCC 2015
- Country
- TEI United States
- CCCC United States
- Employees
- TEI N/A
- CCCC N/A
- Industry
- TEI Finance Companies
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- TEI Finance
- CCCC Health Care
- Exchange
- TEI Nasdaq
- CCCC Nasdaq
- Market Cap
- TEI 256.5M
- CCCC 244.9M
- IPO Year
- TEI N/A
- CCCC 2020
- Fundamental
- Price
- TEI $5.13
- CCCC $1.25
- Analyst Decision
- TEI
- CCCC Buy
- Analyst Count
- TEI 0
- CCCC 4
- Target Price
- TEI N/A
- CCCC $12.50
- AVG Volume (30 Days)
- TEI 142.4K
- CCCC 1.1M
- Earning Date
- TEI 01-01-0001
- CCCC 05-07-2025
- Dividend Yield
- TEI 10.51%
- CCCC N/A
- EPS Growth
- TEI N/A
- CCCC N/A
- EPS
- TEI N/A
- CCCC N/A
- Revenue
- TEI N/A
- CCCC $35,584,000.00
- Revenue This Year
- TEI N/A
- CCCC N/A
- Revenue Next Year
- TEI N/A
- CCCC $36.31
- P/E Ratio
- TEI N/A
- CCCC N/A
- Revenue Growth
- TEI N/A
- CCCC 71.44
- 52 Week Low
- TEI $4.35
- CCCC $1.09
- 52 Week High
- TEI $5.39
- CCCC $7.66
- Technical
- Relative Strength Index (RSI)
- TEI 44.18
- CCCC 32.58
- Support Level
- TEI $4.78
- CCCC $1.09
- Resistance Level
- TEI $5.20
- CCCC $1.32
- Average True Range (ATR)
- TEI 0.13
- CCCC 0.15
- MACD
- TEI -0.01
- CCCC 0.02
- Stochastic Oscillator
- TEI 50.72
- CCCC 25.58
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments and Money Market Funds.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.